Patricio O’Donnell

Patricio O’Donnell

Company: Takeda Pharmaceuticals

Job title: Executive Medical Director and Head, Neurocircuitry Biomarkers


Patricio O’Donnell combines an outstanding academic career in Neuroscience with experience in drug discovery and development for neuropsychiatric indications. He is an Executive Medical Director in the Neuroscience Translational Medicine group at Takeda. Dr. O’Donnell grew up in Buenos Aires, Argentina and earned his M.D. and Ph.D. degrees from the University of Buenos Aires. Dr. O’Donnell worked as a postdoctoral fellow with Anthony Grace at the University of Pittsburgh, where he pioneered studies on the physiological properties of the nucleus accumbens, and then moved on to establishing his own research program at Albany Medical College. In 2006 he was recruited by the University of Maryland, and in 2013 he moved to Pfizer. He is the recipient of numerous awards including the 2010 National Alliance for Schizophrenia and Depression Distinguished Investigator Award. Dr. O’Donnell is a fellow in the American College of Neuropsychopharmacology (ACNP), chaired several conferences including the 2009 Gordon Conference on Catecholamines and the Winter Conference on Brain Research in 2012 and 2013. Dr. O’Donnell has authored over 100 scientific papers, served or serves on the Editorial Boards of the Journal of Neuroscience, Neuropsychopharmacology, The International Journal of Neuropsychopharmacology, Schizophrenia Bulletin, and the Journal of Pharmacology & Experimental Therapeutics, among others, and sat on advisory committees of the National Institutes of Health. He serves on the scientific advisory board of several private foundations and has advised major pharmaceutical and biotech companies. Before joining Takeda, Dr. O’Donnell led discovery efforts for Psychiatry and Pfizer and prior to that he was a Professor of Anatomy & Neurobiology and Psychiatry at the University of Maryland School of Medicine.


Live Q&A 10:30 am

Read more

day: Day One

Advancing Neurophysiology & Cognition Translational Biomarkers to Drive Drug Development for Neuropsychiatric Disorders 9:40 am

• Addressing challenges in drug development for psychiatry requires establishing and validating translational biomarkers • Biomarkers that capture modulation of neural function are key for pharmacodynamic assessments in disease-relevant circuits • Objective digital measures can overcome the lack of precision in current clinical tools • The ultimate goal is to move towards precision medicine in…Read more

day: Day One

Kick-off Panel Discussion: What is Preventing Experts from Redefining the Field & Developing Transformative Drugs for Psychiatric Patients in Need? 9:10 am

• Poor understanding of the disease biology for successful target selection • Heterogenous patient selection and low patient adherence • Animal models that lack translatability • Low precision of clinical endpoints • The need for more translatable biomarkers • Have we defined psychiatric disorders correctly yet? Download the event guide for full session details  Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.